Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amcenestrant in ER+ advanced breast cancer
NCT03284957Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Sep 2017
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of amcenestrant in breast cancer, sponsored by Sanofi. Started Sep 2017; status: terminated.
02
Drugs
amcenestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03284957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03284957.